Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Myelodysplastic Syndromes With Excess Blasts”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00003335
What this trial is testing

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Case Comprehensive Cancer Center 44
Early research (Phase 1)Study completedNCT00990587
What this trial is testing

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Who this might be right for
Hematologic MalignancyAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT07779031
What this trial is testing

A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

Who this might be right for
Acute Myeloid Leukaemia (AML)MDS (Myelodysplastic Syndrome)
Liping Dou 58
Not applicableStudy completedNCT00296023
What this trial is testing

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
University of California, San Francisco 25
Testing effectiveness (Phase 2)UnknownNCT00022321
What this trial is testing

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Early research (Phase 1)Study completedNCT00988715
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePreviously Treated Myelodysplastic Syndrome+6 more
Fred Hutchinson Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT03128034
What this trial is testing

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia+9 more
Fred Hutchinson Cancer Center 75
Testing effectiveness (Phase 2)Looking for participantsNCT03670966
What this trial is testing

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission+9 more
Fred Hutchinson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT01522976
What this trial is testing

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Who this might be right for
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2+4 more
National Cancer Institute (NCI) 282
Testing effectiveness (Phase 2)Looking for participantsNCT05365035
What this trial is testing

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Who this might be right for
Myelodysplastic SyndromesMyeloproliferative Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT00014469
What this trial is testing

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes+1 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Not applicableStudy completedNCT01095874
What this trial is testing

Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study

Who this might be right for
Myelodysplasia
Saint-Louis Hospital, Paris, France 164
Testing effectiveness (Phase 2)Looking for participantsNCT07607418
What this trial is testing

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Who this might be right for
AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Ruijin Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00776503
What this trial is testing

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 52
Testing effectiveness (Phase 2)Study completedNCT00053287
What this trial is testing

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Case Comprehensive Cancer Center 42
Testing effectiveness (Phase 2)Looking for participantsNCT02727803
What this trial is testing

Personalized NK Cell Therapy in CBT

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia+23 more
M.D. Anderson Cancer Center 100
Large-scale testing (Phase 3)UnknownNCT00043134
What this trial is testing

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 220
Testing effectiveness (Phase 2)WithdrawnNCT00003984
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
European Organisation for Research and Treatment of Cancer - EORTC
Testing effectiveness (Phase 2)Looking for participantsNCT04644016
What this trial is testing

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Who this might be right for
AMLALLMDS+6 more
Memorial Sloan Kettering Cancer Center 31
Next Page